Design Therapeutics Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period fromtoCommission File Number: 001-40288 Design Therapeutics, Inc.(Exact Name of Registrant as Specified in its Charter) Delaware(State or other jurisdiction ofincorporation or organization) 6005 Hidden Valley Road, Suite 110Carlsbad, California(Address of principal executive offices) Registrant’s telephone number, including area code: (858) 293-4900 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☒ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ The number of outstanding shares of the registrant’s common stock, $0.0001 par value per share, as of April 23, 2026, was62,456,974. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements that involve risks anduncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities LitigationReform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in thisQuarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as“anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,”“project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these words or other comparable terminology. Theseforward-looking statements include, but are not limited to, statements about: •our plans to research, develop and commercialize our product candidates; •our expectations for clinical development of our program in Friedrich ataxia and announcing data therefrom and thetiming thereof;•the side effect profile observed in nonclinical testing and early clinical testing of DT-216P2 being indicative of the sideeffect profile that may be expected in the future;•the initiation, progress, success, cost and timing of our nonclinical studies, clinical trials and product developmentactivities;•the therapeutic potential of our product candidates, and the disease indications for which we intend to develop ourproduct candidates;•our ability and timing to advance our product candidates into, and to successfully initiate, conduct, enroll and complete,clinical trials;•our ability to manufacture our product candidates for clinical development and, if approved, for commercialization, andthe timing and costs of such manufacture;•the performance of third parties in connection with the development and manufacture of our product candidates,including third parties conducting our nonclinical studies and clinical trials as well as third-party suppliers andmanufacturers;•our ability to obtain funding for our operations, including funding necessary to initiate and complete clinical trials ofour product candidates;•the size and growth of the potential markets for our product candidates and our ability to serve those markets;•the potential scope, duration and value of our intellectual property rights;•our ability, and the ability of our licensors, to obtain, maintain, defend and enforce intellectual property rightsprotecting our platform technologies and product candidates, and our ability to develop and commercialize our productcandidates without infringing the proprietary rights of third parties;•our ability to re